Piper Jaffray Upgrades Pacific Biosciences of California (PACB) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Pacific Biosciences of California, Inc. (PACB) Tops Q2 EPS by 2c
August 1, 2013 5:23 PM EDTPacific Biosciences of California, Inc. (NASDAQ: PACB) reported Q2 EPS of ($0.33), $0.02 better than the analyst estimate of ($0.35).
For earnings history and earnings-related data on Pacific Biosciences of California, Inc. (PACB) click here.... More
